L-lysine supplementation improved glycemic control, decreased protein glycation, and insulin resistance in type 2 diabetic patients
L-lysine supplementation improved glycemic control, decreased protein glycation, and insulin resistance in type 2 diabetic patients
复制标题
DOI：
10.1007/s13410-021-00931-x
复制
发表时间：
2021-02-17
影响因子：
0.9
通讯作者：
Kebriaeezadeh, Abbas
中科院分区：
文献类型：
--
作者：
Mirmiranpour, Hossein;Bathaie, S. Zahra;Kebriaeezadeh, Abbas
背景：在糖尿病大鼠模型和体外实验中，赖氨酸治疗可减少2型糖尿病相关并发症的发生。目的/假设：在单盲随机临床试验中，我们观察了L-赖氨酸(Lys)对2型糖尿病患者的干预作用。试验组口服赖氨酸3g/d。结果试验组空腹血糖、胰岛素、HOMA-IR、HSP70、LCAT、PON1、AOPP、FRAP均有明显改善。糖化血红蛋白和尿糖显著降低，糖化血红蛋白与空腹血糖、果糖胺与空腹血糖、胰岛素和空腹血糖均呈正相关，空腹血糖与尿糖呈正相关，提示赖氨酸可预防糖尿病并发症。肝肾功能检查未见明显变化，提示Lys对患者无明显毒性。结论：Lys抑制了2型糖尿病患者的蛋白糖化，改善了血糖控制，提高了抗氧化标志物水平，可建议联合口服降糖药治疗糖尿病，以预防血管危险因素和其他糖尿病并发症。
Background Lysine treatment decreased diabetic complications associated with type 2 diabetes in the rat models of diabetes and in vitro.Aims/hypothesis Herein, in a single-evaluator-blinded, randomized clinical trial, we investigated the effect of L-Lysine (Lys) intervention in type 2 diabetic patients.Methods Two groups of type 2 diabetic patients (15 females and 10 males in each group) who were under treatment with glibenclamide and metformin underwent a short term (3 months), trial. The test group was orally administered with 3 g/day of Lys. Clinical and biochemical parameters of all patients were measured prior to and after the experimental period and were statistically analyzed.Results Among the serum parameters, FBS, insulin, HOMA-IR, HSP 70, LCAT, PON1, AOPP, and FRAP improved significantly in the test group. A significant decrease in HbA1c and urine glucose accompanying with positive correlations between HbA1c and FBS, fructosamine and both FBS and HbA1c, HOMA with both insulin and FBS, and FBS with urine glucose indicates that Lys prevents diabetes complications. There were no significant changes in the liver and kidney function tests indicating no toxicity of Lys for patients.Conclusions/interpretation In conclusion, Lys inhibited protein glycation, improved glycemic control, and increased antioxidant markers in type 2 diabetic patients; thus, it could be suggested for combinatorial therapy of diabetes with oral hypoglycemic agents to protect against vascular risk factors and other diabetic complications.